Chimerix, Inc.
CMRXNASDAQHealthcare
$8.54
+$0.00(+0.00%)
Market Cap$801084452
P/E Ratio—
52W High$8.55
52W Low$0.75
Chimerix, Inc. (CMRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CMRX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2025Report Date: May 7, 2025EPS Actual
-$0.25
Est. -$0.27 · +7.4%
Revenue
—
Fiscal Period
Q2 FY2025
FY ends December
Report Date
May 7, 2025
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
CMRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q2 FY2025 | May 7, 2025 | -$0.27 | -$0.25 | +7.4% | — | — | — |
| ▲ Q1 FY2025 | Mar 21, 2025 | -$0.26 | -$0.25 | +3.9% | $0.00B | $0.00B | -81.7% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.24 | -$0.26 | -8.3% | $0.00B | $0.00B | -62.9% |
| — Q3 FY2024 | Aug 13, 2024 | -$0.23 | -$0.23 | +0.0% | $0.00B | $0.00B | +115.0% |
| ▼ Q2 FY2024 | May 1, 2024 | -$0.21 | -$0.25 | -19.1% | — | $0.00B | — |
| ▲ Q1 FY2024 | Feb 29, 2024 | -$0.23 | -$0.20 | +13.0% | $0.00B | $0.00B | -93.3% |
| ▼ Q4 FY2023 | Nov 2, 2023 | -$0.22 | -$0.27 | -22.7% | $0.00B | $0.00B | -81.7% |
| ▲ Q3 FY2023 | Aug 3, 2023 | -$0.23 | -$0.21 | +8.7% | $0.00B | $0.00B | -88.7% |
Q2 FY2025
May 7, 2025Beat
EPS Actual
-$0.25
EPS Est.
-$0.27
EPS Surpr.
+7.4%
Revenue
—
Q1 FY2025
Mar 21, 2025Beat
EPS Actual
-$0.25
EPS Est.
-$0.26
EPS Surpr.
+3.9%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.26
EPS Est.
-$0.24
EPS Surpr.
-8.3%
Revenue
$0.00B
Q3 FY2024
Aug 13, 2024
EPS Actual
-$0.23
EPS Est.
-$0.23
EPS Surpr.
+0.0%
Revenue
$0.00B
Q2 FY2024
May 1, 2024Miss
EPS Actual
-$0.25
EPS Est.
-$0.21
EPS Surpr.
-19.1%
Revenue
—
Q1 FY2024
Feb 29, 2024Beat
EPS Actual
-$0.20
EPS Est.
-$0.23
EPS Surpr.
+13.0%
Revenue
$0.00B
Q4 FY2023
Nov 2, 2023Miss
EPS Actual
-$0.27
EPS Est.
-$0.22
EPS Surpr.
-22.7%
Revenue
$0.00B
Q3 FY2023
Aug 3, 2023Beat
EPS Actual
-$0.21
EPS Est.
-$0.23
EPS Surpr.
+8.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q3 FY2026 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q2 FY2026 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Q1 FY2026 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q4 FY2025 | $0.03 | $0.03 | $0.03 | 1 |
| Q3 FY2025 | $-0.31 | $-0.31 | $-0.31 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2025 | May 7, 2025 | +7.4% | $8.54 | — | — |
| ▲ Q1 FY2025 | Mar 21, 2025 | +3.9% | $8.47 | $8.50 | +0.35% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -8.3% | $1.01 | $0.94 | -7.42% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +0.0% | $0.82 | $0.77 | -6.16% |
| ▼ Q2 FY2024 | May 1, 2024 | -19.1% | $0.94 | $0.95 | +1.06% |
| ▲ Q1 FY2024 | Feb 29, 2024 | +13.0% | $1.24 | $1.15 | -7.26% |
| ▼ Q4 FY2023 | Nov 2, 2023 | -22.7% | $0.96 | $0.98 | +2.08% |
| ▲ Q3 FY2023 | Aug 3, 2023 | +8.7% | $1.18 | $1.16 | -1.69% |
Q2 FY2025—
Report Date
May 7, 2025
EPS Beat/Miss
+7.4%
Price Before
$8.54
Price After
—
Q1 FY2025+0.35%
Report Date
Mar 21, 2025
EPS Beat/Miss
+3.9%
Price Before
$8.47
Price After
$8.50
Q4 FY2024-7.42%
Report Date
Nov 7, 2024
EPS Beat/Miss
-8.3%
Price Before
$1.01
Price After
$0.94
Q3 FY2024-6.16%
Report Date
Aug 13, 2024
EPS Beat/Miss
+0.0%
Price Before
$0.82
Price After
$0.77
Q2 FY2024+1.06%
Report Date
May 1, 2024
EPS Beat/Miss
-19.1%
Price Before
$0.94
Price After
$0.95
Q1 FY2024-7.26%
Report Date
Feb 29, 2024
EPS Beat/Miss
+13.0%
Price Before
$1.24
Price After
$1.15
Q4 FY2023+2.08%
Report Date
Nov 2, 2023
EPS Beat/Miss
-22.7%
Price Before
$0.96
Price After
$0.98
Q3 FY2023-1.69%
Report Date
Aug 3, 2023
EPS Beat/Miss
+8.7%
Price Before
$1.18
Price After
$1.16
Avg Beat Reaction-3.69%
Avg Miss Reaction-1.43%
Beat Rate5 / 8 quarters
Largest Move-7.42% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CMRX ends December
Chimerix, Inc. (CMRX) most recently reported earnings on May 7, 2025 for Q2 FY2025, posting EPS of $-0.25 — beating the analyst consensus of $-0.27 by +7.4%. CMRX has beaten EPS estimates for 2 consecutive quarters. The next CMRX earnings date is expected around September 1, 2026.
Each quarter, investors track CMRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CMRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CMRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CMRX earnings · 5 questionsChimerix, Inc.'s next earnings report is expected around September 1, 2026. CMRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CMRX historically reports after market close (AMC).
CMRX earnings datewhen is CMRX earningsCMRX next earnings datewhen does CMRX report earningsCMRX earnings calendar
▸ Source: FMP · Chimerix, Inc. SEC filings · US GAAP · Chimerix, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026